Document 0903
 DOCN  M95A0903
 TI    Granulocyte growth factors: achieving a consensus.
 DT    9510
 AU    Boogaerts M; Cavalli F; Cortes-Funes H; Gatell JM; Gianni AM; Khayat D;
       Levy Y; Link H; University Hospital, Leuven, Belgium.
 SO    Ann Oncol. 1995 Mar;6(3):237-44. Unique Identifier : AIDSLINE
       MED/95336959
 AB    A consensus meeting held under the auspices of the European School of
       Oncology concluded that the use of granulocyte growth factors is
       definitely indicated, or acceptable given existing evidence, in the
       following circumstances: to alleviate congenital neutropenia; in the
       mobilisation of peripheral blood progenitor cells for autotransfusion;
       to encourage engraftment following bone marrow transplantation and in
       cases of failed engraftment; to support continuation of ganciclovir
       anti-CMV therapy in certain patients with AIDS, where the switch to
       foscarnet is contraindicated or where toxicity to foscarnet develops. It
       was also agreed that there is an overwhelming need for carefully
       controlled clinical trials in a wide range of indications in which
       growth factor use may improve outcome. In the majority of tumours, the
       possible benefit of dose optimisation and intensification, and therefore
       the role of growth factors in support of such measures has still to be
       defined. Extramedullary toxicities may in these instances become dose
       limiting.
 DE    AIDS-Related Opportunistic Infections/THERAPY  Bone Marrow
       Transplantation  Granulocyte Colony-Stimulating Factor/*THERAPEUTIC USE
       Hematologic Diseases/DRUG THERAPY/THERAPY  Hematopoietic Stem Cell
       Transplantation  Hematopoietic Stem Cells  Human  Neoplasms/DRUG
       THERAPY/THERAPY  Neutropenia/THERAPY  CONSENSUS DEVELOPMENT CONFERENCE
       JOURNAL ARTICLE  REVIEW

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).